Bob Azelby, CEO of Eliem Therapeutics, pictured above. (Doug Pensinger/Getty Images) Eliem Therapeutics emerged from stealth mode with $80 million in financing that will be used to develop therapeutics aimed at treating neuronal excitability disorders such as chronic pain, depression, epilepsy and anxiety. The disorders Eliem is targeting have a wide patient population across the globe. […]